HFpEF vs. HFrEF: Can microRNAs advance the diagnosis?

European Journal of Heart Failure

Volumn 17, Issue 4, 2015, Pages 351-354

  Schmitter, Daniela ^a   Voors, Adriaan A ^b   Van Der Harst, Pim ^b  

^a Momentum Research   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

EFdiagnosis; heart failureheart failure with preserved ejection fractionmicro; HFp; RNAbiomarker

Indexed keywords

MICRORNA; MICRORNA 125A 5P; MICRORNA 146A; MICRORNA 190A; MICRORNA 221; MICRORNA 30C; MICRORNA 328; MICRORNA 375; MICRORNA 550A 5P; MICRORNA 638; NEUROTROPHIN; PROTEIN P53; UNCLASSIFIED DRUG;

BODY MASS; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; HYPERTENSION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 84964253334     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.259     Document Type: Review

References (13)

1. Pellicori P, Cleland JG,. Update on management of heart failure with preserved ejection fraction. Curr Opin Cardiol 2015;doi: 10.1097/HCO.0000000000000152.
2. Lok DJ, Klip IT, Voors AA, Lok SI, Bruggink-André de la Porte PW, Hillege HL, Jaarsma T, van Veldhuisen DJ, van der Meer P,. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail 2014; 16: 958-966.
3. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
4. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R, Reinhardt F, Liao R, Krieger M, Jaenisch R, Lodish HF, Blelloch R,. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009; 105: 585-594.
5. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT,. Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31: 367-373.
6. Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG, van Rooij E,. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 2013; 15: 650-659.
7. Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat-Hamedani F, Kayvanpour E, Kloos W, Backe C, Thanaraj A, Brefort T, Beier M, Hardt S, Meese E, Katus HA, Meder B,. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J 2013; 34: 2812-2822.
8. Nair N, Gupta S, Collier IX, Gongora E, Vijayaraghavan K,. Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF? Int J Cardiol 2014; 175: 395-399.
9. 1, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY, Chong JP, Ng JY, Chen YT, Chan MM, Chen Z, Yeo PS, Ng TP, Ling LH, Sim D, Leong KT, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Lam CS, Jeyaseelan K, Richards AM,. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015; 17: 393-404.
10. Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, McDonald K, Grote-Levi L, Thum T,. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015; 17: 405-415.
11. Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM,. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-1147.
12. Chini VP,. Micro-RNAs and next generation sequencing: new perspectives in heart failure. Clin Chim Acta 2014;pii: S0009-8981(14)00525-7.
13. Caroli A, Cardillo MT, Galea R, Biasucci LM,. Potential therapeutic role of microRNAs in ischemic heart disease. J Cardiol 2013; 61: 315-320.